Format

Send to

Choose Destination
Acta Ophthalmol. 2010 Dec;88(8):896-900. doi: 10.1111/j.1755-3768.2009.01582.x.

Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes.

Author information

1
Tokyo Women's Medical University, Japan. 51026745@mail.goo.ne.jp

Abstract

PURPOSE:

To compare the efficacy of bromfenac sodium ophthalmic solution (BF) and a steroidal solution (ST) administered prophylactically against cystoid macular oedema and anterior-chamber inflammation after phacoemulsification and intraocular lens implantation and to assess macular thickness changes using optical coherence tomography (OCT).

METHODS:

In this prospective study, 62 eyes of 62 patients were randomized to either the BF group (n=31) or the ST group (n =31). The average perifoveal thickness (AFT) was measured by OCT preoperatively, and 1 day and 1, 2, 4 and 6 weeks postoperatively. The best-corrected visual acuity, intraocular pressure and flare in the anterior chamber were recorded at each visit. The same method was used to compare patients with non-proliferative diabetic retinopathy (NPDR) in the BF (n = 16) and ST (n =11) groups.

RESULTS:

In the analysis of all patients, flare in the anterior chamber was significantly (p = 0.007) lower in the BF group 2 weeks postoperatively. In patients with NPDR, the anterior chamber flare values were significantly lower in the BF group at 4 weeks (p = 0.0009) and 6 weeks (p = 0.005). The AFT values were significantly lower in the BF group at 4 weeks (p < 0.0001) and 6 weeks (p < 0.0001). No adverse events occurred in either group.

CONCLUSION:

BF suppressed anterior chamber inflammation and increasing retinal thickening after cataract surgery in patients with NPDR.

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center